CASE STUDIES IN ENHANCING DRUG PERFORMANCE

WANT INCREASED BIOAVAILABILITY?

Zylö’s technology has overcome the bioavailability limitations of AEA, an endocannabinoid: AEA-loaded Z-pods® demonstrated significant reduction in lesion count and severity in a lupus model as compared with AEA without Z-pods.

TARGETING PORES OR FOLLICLES?

We can help.  We are in discussions with cosmetic, OTC, and Rx companies to improve product performance through specific targeting of pores and follicles for indications such as alopecia and acne.

NEED IMPROVED SOLUBILITY?

Approached by a firm whose drug candidate was only 0.3% soluble, Zylö was able to increase the solubility factor almost 20-fold using its Z-pod® technology.